2 ms·
This is good news for big pharma. Transgender medicine presents a huge revenue opportunity. Monetizing a human by charging them a subscription fee to be who th
by sn0w_crash 4y ago
This is good news for big pharma. Transgender medicine presents a huge revenue opportunity.
Monetizing a human by charging them a subscription fee to be who they identify as is a new subscription model that can last a lifetime.
The LTV is huge. The issue is that not many folks identify as trans. If anything, it would be in the interest of Pfizer to encourage more kids to question their identity and transition.
- salawat 4y agoThey already have that with ...most patients. Didn't you read the Goldman Sachs analysis? Cures aren't good business. Symptom mitigation is where it's at.
- DanBC 4y agoYou're claiming that providing a cheap, unpatented, medication to 0.5% of the population is some kid of growth opportunity when the same meds are used for nearly 1 in 3 women?